Search

Your search keyword '"Dienstmann, Rodrigo"' showing total 785 results

Search Constraints

Start Over You searched for: Author "Dienstmann, Rodrigo" Remove constraint Author: "Dienstmann, Rodrigo"
785 results on '"Dienstmann, Rodrigo"'

Search Results

2. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

7. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

8. Electric hand warmer versus observation to avoid discomfort during scalp cooling for chemotherapy-induced alopecia prevention: a randomized study

10. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

11. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon

12. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients

13. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

14. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

15. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

16. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

17. Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays.

18. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean

22. Oncologia de Precisão

23. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

24. Evolving and Improving the Sustainability of Molecular Tumor Boards: The Value and Challenges.

25. The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients.

28. Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays

29. Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer

31. FIGURE 4 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

34. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

38. Weakly supervised deep learning predicts immunotherapy response in solid tumors based on PD-L1 expression

39. Figure S3 from Early-Stage Breast Cancer Detection in Breast Milk

40. Data from Early-Stage Breast Cancer Detection in Breast Milk

42. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

47. Early-Stage Breast Cancer Detection in Breast Milk

50. Precision cancer medicine: Concepts, current practice, and future developments

Catalog

Books, media, physical & digital resources